Lubetkin E I, Lipson D A, Palevsky H I, Kotloff R, Morris J, Berry G T, Tino G, Rosato E F, Berlin J A, Wurster A B, Kaiser L R, Lichtenstein G R
Department of Medicine, Children's Hospital of Philadelphia, Pennsylvania, USA.
Am J Gastroenterol. 1996 Nov;91(11):2382-90.
Recently, lung transplantation has been performed with increasing frequency and improved outcomes. GI complications have been observed and reported in patients undergoing cardiac and renal transplantations but only recently have been reported in patients after lung transplantation. No large cohort has been systematically analyzed for all GI complications after lung transplantation. The present study describes, categorizes, and assesses risk factors for the development of such GI complications.
Records of 45 patients who underwent 47 single or bilateral orthotopic lung transplants between November 1991 and January 1994 were reviewed.
Twenty-three patients (51%) had 64 GI complications requiring 13 operations on eight patients. The incidence of major abdominal procedures in the entire transplant cohort was 18% (8/45). Their operative mortality rate was 63% (5/8). Eighteen different types of nonoperative complications occurred and were subclassified into major and minor complications. Complications were defined as major if they required medical or surgical intervention and altered patient management. Most GI complications (73%) occurred within 1 month after transplantation. No risk factors were identified to ascertain who will develop GI complications.
GI complications occur in more than one-half of lung transplant recipients early after transplantation and in the absence of identifiable risk factors. Because there are no precedent risk factors to suggest who will develop GI complications, clinicians must be alert to any warning signs and symptoms. The majority of complications are nonoperative, responding to conservative therapy, but there is a higher overall mortality rate for patients requiring operative intervention, necessitating an aggressive search for major, life-threatening complications in these immunosuppressed patients.
近年来,肺移植的开展频率不断增加,治疗效果也有所改善。心脏和肾移植患者中已观察并报道了胃肠道并发症,但肺移植患者的此类并发症直到最近才被报道。目前尚无针对肺移植后所有胃肠道并发症进行系统分析的大型队列研究。本研究描述、分类并评估了此类胃肠道并发症发生的危险因素。
回顾了1991年11月至1994年1月期间接受47次单肺或双肺原位移植的45例患者的记录。
23例患者(51%)出现64例胃肠道并发症,其中8例患者需要进行13次手术。整个移植队列中腹部大手术的发生率为18%(8/45)。其手术死亡率为63%(5/8)。发生了18种不同类型的非手术并发症,并被分为主要并发症和次要并发症。如果并发症需要药物或手术干预并改变患者的治疗方案,则被定义为主要并发症。大多数胃肠道并发症(73%)发生在移植后1个月内。未发现可确定谁会发生胃肠道并发症的危险因素。
超过一半的肺移植受者在移植后早期出现胃肠道并发症,且无明确的危险因素。由于没有先例性危险因素提示谁会发生胃肠道并发症,临床医生必须警惕任何警示症状和体征。大多数并发症为非手术性,可通过保守治疗缓解,但需要手术干预的患者总体死亡率较高,因此必须积极寻找这些免疫抑制患者中严重的、危及生命的并发症。